Trial Profile
Open Label Phase Ib/II, Multicenter Study of the Combination of RO5479599 With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) of Squamous Histology Who Have Not Received Prior Chemotherapy or Targeted Therapy for NSCLC
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 Feb 2019
Price :
$35
*
At a glance
- Drugs Lumretuzumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 24 Nov 2016 Status changed from suspended to discontinued. As per results published in the European Clinical Trials Database results record, this trial was discontinued due to a strategic decision taken by the sponsor to stop further development of RO5479599. This trial was conducted in Spain, Canada and Denmark. Planned trial sites for this trial also included Korea, Netherlands, UK, France, Germany, Norway and USA
- 18 Nov 2016 This trial has been completed in Spain (end date: 14 Mar 2016).
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress